Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Udai Banerji

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert Jones, Ruth Plummer, Victor Moreno, et al.
Cancer Research|June 24, 2026
Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung CancerMatthew A Clarke, Charlie George Barker, Ashley Nicholls, et al.
Cancer|October 8, 2016
A study of motivations and expectations of patients seen in phase 1 oncology clinicsSaoirse O Dolly, Eleftheria Kalaitzaki, Martina Puglisi, et al.
Molecular Cancer Therapeutics|May 5, 2012
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancerCraig P Carden, Adam Stewart, Parames Thavasu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumorsCristiana Sessa, Geoffrey I Shapiro, Kapil N Bhalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2020
Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical TrialsAngelika Terbuch, Crescens Tiu, Irene Moreno Candilejo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitorsMalaka Ameratunga, Maxime Chénard-Poirier, Irene Moreno Candilejo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2011
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumorsSimon Pacey, Richard H Wilson, Mike Walton, et al.
Molecular Cancer Therapeutics|January 26, 2019
First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid TumorsAkihiko Shimomura, Noboru Yamamoto, Shunsuke Kondo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2012
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumorsMaria Martinez-Garcia, Udai Banerji, Joan Albanell, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert Jones, Ruth Plummer, Victor Moreno, et al.
Cancer Research|June 24, 2026
Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung CancerMatthew A Clarke, Charlie George Barker, Ashley Nicholls, et al.
Cancer|October 8, 2016
A study of motivations and expectations of patients seen in phase 1 oncology clinicsSaoirse O Dolly, Eleftheria Kalaitzaki, Martina Puglisi, et al.
Molecular Cancer Therapeutics|May 5, 2012
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancerCraig P Carden, Adam Stewart, Parames Thavasu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumorsCristiana Sessa, Geoffrey I Shapiro, Kapil N Bhalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2020
Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical TrialsAngelika Terbuch, Crescens Tiu, Irene Moreno Candilejo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitorsMalaka Ameratunga, Maxime Chénard-Poirier, Irene Moreno Candilejo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2011
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumorsSimon Pacey, Richard H Wilson, Mike Walton, et al.
Molecular Cancer Therapeutics|January 26, 2019
First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid TumorsAkihiko Shimomura, Noboru Yamamoto, Shunsuke Kondo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2012
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumorsMaria Martinez-Garcia, Udai Banerji, Joan Albanell, et al.
Pageof 13